Targeting MicroRNAs for Metabolic Disorders
AssigneeRegulus Therapeutics Inc.
InventorsBalkrishen Bhat, Neil W. Gibson, Diedre MacKenna, Brandee Wagner, David P. Bartel
Life of this patent
Estimating the term…
Abstract
Described herein are compounds comprising modified oligonucleotides that are complementary to miR-103 and/or miR-107 and methods of treating diseases and disorders using the compounds.
Claims21
to 49. (canceled)
A method for reducing a blood glucose level of a subject having an elevated blood glucose level or preventing or delaying the onset of an elevated blood glucose level in a subject at risk for developing an elevated glucose level, comprising administering to the subject a therapeutically effective amount of a compound comprising the structure (II):
- wherein X is a phosphodiester linkage;
- each N of Nm is a deoxyadenosine (A);
- m is 2;
- Y is a phosphodiester linkage;
- and MO is 5′-CSASASUSGSCSUSGSCSASAACSASASUSGSCSUSGSCSAS- 3′, wherein each nucleoside followed by a subscript “S” is a S-cEt nucleoside, each nucleoside not followed by a subscript is a deoxynucleoside, and each internucleoside linkage between two S-cEt nucleosides is a phosphorothioate linkage, and the remaining internucleoside linkages are phosphodiester linkages;
- and wherein Y is linked to the 3′ terminus of MO, wherein the compound is comprised in a pharmaceutical composition.
A method for reducing a blood glucose level of a subject having an elevated blood glucose level or preventing or delaying the onset of an elevated blood glucose level in a subject at risk for developing an elevated glucose level, comprising administering to the subject a therapeutically effective amount of a compound having the structure:
- wherein the compound is comprised in a pharmaceutical composition.
Dependencies are inferred from the claim text.